ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases

Mihaela Aldea,1 Benjamin Besse1,2 and Lizza EL Hendriks3

1. Department of Cancer Medicine, Gustave Roussy, Villejuif, France; 2. University Paris Saclay, Orsay, France; 3. Department of Pulmonary Diseases, School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, The Netherlands

DOI: https://doi.org/10.17925/EOH.2020.16.1.18

In anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer, brain metastases occur in 22–33% of cases at diagnosis and could reach up to 70% after crizotinib failure. Next-generation ALK inhibitors (ngALKi) have superior intracranial activity and prolonged responses compared with crizotinib and chemotherapy, as was shown in treatment-naïve or crizotinib pre-treated patients, irrespective of prior brain irradiation. Nevertheless, central nervous system relapse is also seen with ngALKi. Tailored treatment is necessary to obtain long-term survival without detrimental effects on cognition. Possible options include profiling secondary mutations to select sequential ngALKi, stereotactic radiotherapy and/or surgery, with the aim to avoid/deter whole brain irradiation.

Keywords

Non-small cell-lung cancer, anaplastic lymphoma kinase, brain metastases, personalised treatment

Disclosures: Benjamin Besse declares the following: research sponsored at Gustave Roussy Cancer Center by AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, Merck Sharp & Dohme, Nektar, OncoRx, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Theratogen Pharmacology; investigator or co-investigator of trials sponsored by AstraZeneca and Blueprint Medicines. Benjamin Besse declares the following: research sponsored at Maastricht University Medical Center from Roche, Genentech, Boehringer Ingelheim and AstraZeneca; advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Roche-GeneTech, Pfizer, Takeda and Merck Sharp & Dohme (all institutions); speaker for Merck Sharp & Dohme; travel/conference reimbursement from Roche-GeneTech, Bristol-Myers Squibb (self), mentorship programme with key opinion leaders funded by AstraZeneca; fees for educational webinars from Quaide (self), interview sessions funded by Roche-GeneTech (institution); local principal investigator of clinical trials sponsored by AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, GlaxoSmithKline, Takeda, Blueprint Medicines and Roche Genentech.

Mihaela Aldea has no financial or non-financial relationships or activities to declare in relation to this article.

Review Process: Double-blind peer review.

Compliance with Ethics: This article is an opinion piece and does not report on new clinical data, or any studies with human or animal subjects performed by any of the authors.

Authorship: The named authors meet the International Committee of Medical Journal Editors (ICMJ) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Access: This article is freely accessible at touchONCOLOGY.com © Touch Medical Media 2020.

Received: 13 April 2020
Accepted: 18 May 2020
Published Online: 27 August 2020

Citation: European Oncology & Haematology. 2020;16(1):18–21

Corresponding Author: Lizza EL Hendriks, Department of Pulmonary Diseases, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands. E: lizza.hendriks@mumc.nl

Support: No funding was received in the publication of this article.
ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases

**Figure 1: Most common treatment sequences and outcomes based on clinical trials**

![Treatment Sequences and Outcomes](image)

In the ASCEND-4 trial (NCT01828099), which evaluated ceritinib in comparison with chemotherapy, CNS progression in patients without baseline brain metastases occurred in 31% of patients; of these patients 30% had an isolated CNS progression.7

**How to proceed with treatment in the case of CNS progression on an ALK inhibitor**

NgALKi have higher intracranial activity compared with chemotherapy or crizotinib.10–13 CNS responses occur early, starting from the first evaluation scan,10 and are durable. The duration of response under ngALKi can reach more than 1 year in crizotinib-naïve patients. Importantly, ngALKi are effective also after crizotinib failure, with intracranial overall response rates (ORR) ranging from 27–87% and a median duration of response of several months (Figure 1). After failing at least two lines of ALKi, the third-generation ALKi, lorlatinib, achieved an intracranial ORR of 53% and an intracranial median duration of response of 14.5 months.10 This impressive activity in heavily pre-treated patients is due to the retained potency of lorlatinib to acquired resistant mutations under prior ALKi (including ALK G1202) and because of its better capacity to penetrate into the CNS (CSF drug concentrations of 75% of plasma levels).10,14 The ASCEND-7 study (NCT02336451), which has been specifically designed to assess the CNS response under ceritinib, has also evaluated leptomeningeal disease. This cohort of patients (n=18) was ceritinib pre-treated in 89% of cases and had prior radiotherapy in 61% of cases. The median PFS was 5.2 months and the median overall survival 7.2 months, longer than that established in patients with historical NSCLC (1–3 months).14

Importantly, data from the above-mentioned clinical trials are not comparable because of different inclusion/evaluation criteria (Table 1).

**Patients with CNS relapse might benefit from a molecularly guided treatment sequence**

Despite an increase in intracranial activity of ngALKi, CNS disease will often eventually relapse. The sequential use of the third-generation ALKi, lorlatinib, after second-generation ALKi, was successful in a global phase II trial (NCT01970865).15 There are currently no clinical trials evaluating a sequential approach between different second-generation ALKi. This might be justified, considering that second-generation ALKi have different 'sensitivity' profiles, according to resistance mutations.1 Thus, a molecularly guided approach tailored to secondary mutations could earn additional treatment lines and also increase the chance of obtaining a CNS response. Another situation that could be encountered is the development of isolated CNS progression, a frequent phenomenon with crizotinib, that could also occur with ngALKi.15 For example, in the ASCEND-4 study evaluating first-line ceritinib versus chemotherapy, 48% of patients failing ceritinib developed isolated CNS progression.2 Isolated CNS progression occurs as either a consequence of resistance alterations or insufficient drug penetration. In the latter case, there may be a retention of sensitising alterations.17

The distinction between these two causes of isolated CNS progression would better guide the treatment sequence between alternate second-generation drugs and third-generation drugs or the use of local therapies, such as cranial irradiation. However, performing a molecular profile in patients with isolated CNS progression is challenging, as it should be performed in CSF rather than in plasma. Plasma circulating tumour DNA is negative in ≥50% of cases of isolated CNS progression, depending on the performance of the technique.17 In the absence of resistance alterations, an insufficient drug concentration in the brain might be responsible. However, currently there are only scarce data in
several patients that investigate ALKi concentrations in the CSF, and there are no CSF penetration data on ALKi dose escalation. For alectinib, dose escalation (900 mg twice daily) has been described in two patients with leptomeningeal disease progression under standard dose of alectinib. 11

Switching to another ngALKi might avoid or defer cranial irradiation

In crizotinib-naïve and crizotinib-resistant patients, second- and third-generation ALKi have CNS activity regardless of brain irradiation history. In patients with NSCLC with asymptomatic brain metastases, there were similar intracranial ORRs in irradiated versus non-irradiated patients, as shown by trials of brigatinib (phase I/II trials) or alectinib. 1,18 In the ALEX trial, there was a HR for disease progression or death favouring alectinib over crizotinib of 0.34 for previously irradiated patients and 0.44 for patients without prior irradiation. 1 Also, patients with active brain metastases had similar intracranial ORR and intracranial median duration of response in irradiated versus non-irradiated tumours in the ASCEND-7 trial, in both crizotinib-naïve or pre-treated patients. 9

The availability of effective systemic treatments for sequential use could thus lead to deferring, or even avoiding, whole brain irradiation, which would spare patients the long-term neurocognitive radio-induced side effects. ALK+ patients are usually young, with a long median overall survival of 6.8 years from diagnosis of stage IV disease. 16 Similarly, long-term effects of stereotactic radiotherapy, such as radionecrosis, could be seen more frequently. Therefore, anticancer strategies should aim to prolong each line of treatment, without adding significant toxicity. For this purpose, when isolated CNS progression relapse is amenable to local treatment, stereotactic radiotherapy or surgery are usually employed, while continuing the same ALKi. As the incidence of radionecrosis is related to the tumour

| Drug/clinical trial | Line of treatment | Type of CNS metastases | CNS screening mandatory | FU CNS imaging mandatory/ frequency | CNS imaging | CNS evaluation criteria | Brain prespecified endpoint |
|---------------------|-------------------|------------------------|------------------------|------------------------------------|-------------|-------------------------|----------------------------|
| Crizotinib 250 mg BID PROFILE 1014 1 NCT01154140 | First-line BM | Stable; treated | Yes | Every 6 weeks if baseline BM; 12 weeks otherwise | CT/MRI | RECI 1.1. | IC-TIP IC-DCR |
| Alectinib 600 mg BID ALEX 4 NCT02075840 | First-line BM | Asymptomatic; treated/untreated | Yes | Every 8 weeks | CT/MRI | RANO-BM | PFS IC-TIP IC-ORR IC-DOR |
| Alectinib 600 mg BID ALUR 12 NCT02604342 | Post-crizotinib and platinum-based CT | Asymptomatic; Symptomatic and ineligible for radiotherapy | Yes | Every 6 weeks | CT/MRI | RECI 1.1. | IC-ORR IC-DCR IC-DOR IC-DOR |
| Crizotinib 750 mg QD fasted ASCEND-4 7 NCT01828099 | First-line BM | Asymptomatic; 60% active BM | Yes | Every 6 weeks through cycle 33, then every 9 weeks | CT/MRI | Modified RECI 1.1. | IC-ORR IC-DCR IC-DOR IC-clinical benefit rate |
| Ceritinib 750 mg QD fasted ASCEND-7 9 NCT02336451 | Crizotinib-naïve/ post-crizotinib BM | Active; LM (arm 5) | Yes | Every 8 weeks | MRI | RECI 1.1. | IC-ORR IC-DCR IC-TTP IC-DOR |
| Brigatinib 180 mg QD ALTA-1L 6 NCT02737901 | First ALKi BM | Asymptomatic; Untreated | Yes | Every 8 weeks through cycle 14, then every 12 weeks | MRI | RECI 1.1. | IC-ORR IC-PFS |
| Brigatinib 180 mg QD ALTA Arm B 8 NCT02094573 | Post-crizotinib and/or chemotherapy BM | Asymptomatic; Active, in the absence of neurological instability and high doses of corticosteroids; LM | Yes | No – only in patients with baseline BM (every 8 weeks through cycle 15, then every 12 weeks) | MRI | RECI 1.1. | IC-ORR IC-DOR IC-PFS |
| Lorlatinib 100 mg QD Global phase I/II NCT01970865 | Crizotinib-naïve, post-crizotinib, post-second-generation ALKi BM | Asymptomatic; treated/untreated | Yes | Every 6 weeks through cycle 30, then every 12 weeks | MRI | RECI 1.1. | IC-ORR IC-DOR Median time to first IC response |

ALKI = anaplastic lymphoma kinase inhibitor; BID = twice a day; BM = brain metastases; CNS = central nervous system; CT = computed tomography; FU = follow-up; IC = intracranial; IC-DCR = intracranial disease control rate; IC-DOR = intracranial duration of response; IC-ORR = intracranial objective response rate; IC-TTP = intracranial time to tumour progression; IC-TTR = intracranial time to treatment response; LM = leptomeningeal carcinomatosis; MRI = magnetic resonance imaging; PD = progression; QD = once a day; RANO-BM = Response Assessment in Neuro-Oncology Brain Metastases; RECIST = Response Evaluation Criteria in Solid Tumors.
size, stereotactic radiotherapy should not be delayed too much. It may be interesting to identify patients who will eventually develop early subsequent extra-CNS progression and who might benefit more from a tyrosine kinase inhibitor switch rather than a local treatment. In isolated CNS progression, a positive liquid biopsy might predict subsequent extra-CNS progression, but these data should be validated in prospective studies.17

Due to the availability and performance of ngALKi, patients can have long-term survival despite the presence of brain metastases.20,21 We hope to witness even more rapid improvement in their management as other promising options are being investigated. These include the addition of bevacizumab in the NCT02521051 trial, novel drugs with promising early CNS efficacy data such as entrectinib (NCT03994796, NCT02568267) or ensartinib (NCT03753685), proof of principle studies in patients who will undergo surgery (e.g., NCT02605746), a new lorlatinib trial in patients without measurable extra-CNS lesions (NCT02927340), trials evaluating upfront radiotherapy and ALKi (e.g., NCT04193007), or radiotherapy concurrent with continuation of the ALKi upon isolated CNS progression during ALKi (e.g., the Dutch multicentre platform trial NL6518/NTR6707).

In conclusion, patients with ALK+ NSCLC with brain metastases greatly benefit from ngALKi, irrespective of prior brain irradiation or the presence of brain involvement at baseline, in the first-line, or after failing crizotinib. The sequential ALKi approach is effective in terms of CNS activity and in obtaining long-term survival. Importantly, whole-brain irradiation can often be deferred or avoided, and patients are spared long-term radio-induced toxicity.

1. Recondo G, Facchinetti F, Gluudsen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Aaf Rev Clin Oncol. 2018;15:694–708.
2. Solomon BJ, Capuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34:2858–65.
3. Costa DB, Kobayashi S, Pardilla SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443–8.
4. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–39.
5. Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29:2214–22.
6. Camidge DR, Kim HI, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Thorac Oncol. 2019;30:v143–4.
7. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) metastatic to the brain. Ann Oncol. 2019;30:v602–3.
8. Zwieglinski M, Neale A: infiltrating the blood-brain barrier in ALK-positive lung cancers. J Clin Oncol. 2018;36:2677–9.
9. Ihde DM, Hansen KH, Paz-Ares Rodriguez L, et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial. J Thorac Oncol. 2020;15:404–15.
10. Novello S, Maionelli J, Chi LI, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409–16.
11. Gadgeel S, Shaw AT, Barlesi F, et al. Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving aldetinib in the phase II NF28763 and NF28761 studies. Lung Cancer (Auckl). 2019;10:125–30.
12. Solomon BJ, Blesee B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1646–57.
13. Zhang YM, Corless CL, et al. Exploratory analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression. J Thorac Oncol. 2020;15:383–91.
14. Gadgeel SM, Gandhi L, Riedi GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small cell lung cancer (AF-002X): results from the dose-finding portion of a phase I/II study. Lancet Oncol. 2014;15:1119–28.
15. Gainor JF, Chi AS, Logan J, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol. 2016;11:2266–70.
16. Pacheco IM, Gao D, Smith D, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol. 2019;14:691–700.
17. Griesinger F, Roepfer I, Potten C, et al. Brain metastases in ALK positive NSCLC – time to adjust current treatment algorithms. Oncotarget. 2018;9;35:181–94.